对线粒体ATP合成途径的肺向反调节,用于 ортотоп瘤抑制
Zhou Jiang1, Songlan Pan2, Jianhua Chen1
1Department of Thoracic Medicine, Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, Central South University, Changsha 410006, China.
Journal of materials chemistry. B
|July 15, 2025
概括
这项研究引入了一种新的纳米医学策略,通过抑制线粒体ATP生产来向癌症. 这种反控制的方法通过在ATP水平正常化时减少药物释放来最大限度地减少副作用.
科学领域:
- 生物医学工程 生物医学工程
- 纳米医学是一种纳米医学.
- 癌症治疗方法 癌症治疗方法
背景情况:
- 腺三酸盐 (ATP) 助长癌症的进展,但由于它在正常细胞中的重要作用,向它是具有挑战性的.
- 现有的ATP向策略缺乏选择性,导致显著的副作用.
- 反抑制是一种自然的调节机制,为向癌症治疗提供了一个潜在的解决方案.
研究的目的:
- 开发一种针对线粒体的纳米医学系统,用于使用反抑制ATP合成来治疗癌症.
- 为控制药物输送创建一个对ATP有反应的金属有机框架 (ZIF-90).
- 为了研究该系统在降低瘤ATP水平的有效性,最小的目标外影响.
主要方法:
- 制造一种对ATP有反应的ZIF-90/AIPH/BE纳米复合体,用于针对线粒体的输送.
- 利用ZIF-90中ATP和Zn2+之间的竞争性结合来触发药物释放.
- 评估纳米复合体的肺积累,线粒体向能力和ATP耗尽功效.
- 实施负反循环以调节基于ATP水平的药物释放.
主要成果:
- 该ZIF-90/AIPH/BE纳米复合体显示出高的肺积累和有效的线粒体向.
- 存在ATP触发了纳米粒子分解和AIPH和贝达基林 (BE) 的释放.
- 释放的AIPH和BE显著减少了ATP的产生,导致线粒体ATP耗尽.
- 观察到一种负反机制,限制了ATP减少后进一步的药物释放.
结论:
- 一个基于ZIF-90的新型ATP响应纳米医疗系统成功开发用于向癌症治疗.
- 反抑制机制有效地控制药物释放,增强治疗特异性并最大限度地减少副作用.
- 这种方法为开发针对癌症等疾病代谢途径的先进纳米药物提供了一个有希望的新途径.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Electron Transport Chain: Complex I and II
15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.0K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Tumor Immunotherapy
664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664


